Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 88,447,000, a decrease of 43% compared to RMB 155,740,000 in 2024[3] - Gross profit for 2025 was RMB 22,127,000, down 65% from RMB 62,786,000 in 2024[3] - The company reported a loss before tax of RMB 31,378,000 for 2025, compared to a profit of RMB 26,309,000 in 2024[3] - Basic and diluted loss per share for 2025 was RMB (0.03), compared to earnings of RMB 0.02 per share in 2024[4] - The company reported a net loss of RMB 29,716,000 for 2025, compared to a profit of RMB 17,204,000 in 2024[34][36] - The company recorded a net loss of approximately RMB 299 million, an increase of RMB 474 million or 270.9% (2024: RMB 175 million) due to the cumulative impact of the aforementioned factors[72] Assets and Liabilities - Total assets less current liabilities decreased to RMB 232,644,000 in 2025 from RMB 260,661,000 in 2024[6] - Non-current assets totaled RMB 57,439,000 as of December 31, 2025, slightly down from RMB 58,686,000 in 2024[5] - Cash and cash equivalents decreased to RMB 21,932,000 in 2025 from RMB 28,226,000 in 2024[5] - Trade receivables decreased to RMB 163,286,000 in 2025 from RMB 174,190,000 in 2024[5] - The total amount of bank borrowings as of December 31, 2025, was RMB 12,764,000, down from RMB 17,712,000 in 2024[43] - As of December 31, 2025, the company had net current assets of approximately RMB 1,752 million (2024: RMB 2,020 million) and cash and cash equivalents decreased by approximately RMB 63 million to about RMB 219 million (2024: RMB 282 million)[73] - The company’s trade payables increased to RMB 1,242,000 in 2025 from RMB 560,000 in 2024[41] - The company has no significant contingent liabilities as of December 31, 2025 (2024: none)[76] - As of December 31, 2025, the company's debt-to-equity ratio decreased by 1.3 percentage points to 5.5% from 6.8% as of December 31, 2024, primarily due to a reduction in interest-bearing bank borrowings[80] Revenue Sources - Revenue from medical imaging film products accounted for about 85% of total revenue in 2025, compared to 76% in 2024[17] - Revenue from medical imaging film products and software decreased by approximately RMB 603 million or 41.2% to about RMB 862 million (2024: RMB 1,465 million) due to lower average selling prices and decreased sales volume[62] - Revenue from medical imaging cloud services decreased by approximately RMB 70 million or 76.1% to about RMB 22 million (2024: RMB 92 million), following the decline in film product sales[63] Expenses - The cost of goods sold for the year was RMB 55,947,000, down from RMB 83,682,000 in 2024, reflecting a decrease of approximately 33%[29] - Other income for the year totaled RMB 6,154,000, a decrease from RMB 8,583,000 in 2024, primarily due to lower government grants[28] - The group incurred employee benefit expenses of RMB 10,711,000 in 2025, compared to RMB 11,884,000 in 2024, indicating a reduction of approximately 10%[29] - The group’s depreciation of property, plant, and equipment increased to RMB 14,038,000 in 2025 from RMB 6,562,000 in 2024, reflecting a significant rise[29] - Operating expenses increased by approximately RMB 22 million or 12.4% to about RMB 200 million (2024: RMB 178 million), mainly due to increased depreciation of property, plant, and equipment[68] Taxation - The company's income tax expense for 2025 was a credit of RMB 1,417,000, compared to an expense of RMB 8,859,000 in 2024[31] - The applicable income tax rate for the company in mainland China is 25%, with a subsidiary qualifying for a reduced rate of 15% due to high-tech enterprise status[32] Strategic Plans - The company plans to expand its customer base and strengthen its market position in Shandong Province by extending its services to other regions[53] - Strategic acquisitions and upgrades of hardware and software are intended to enhance the supply of medical imaging cloud services[53] - The company believes that developing medical imaging cloud services and expanding its product range will increase long-term revenue and strengthen its role as a one-stop medical imaging solution provider[56] - The company aims to participate in trade exhibitions to promote its brand and increase market visibility[53] Shareholder Information - The company has no plans to declare dividends for the year 2025, consistent with 2024[33] - The company has not engaged in any purchase, sale, or redemption of its listed securities during the year[89] - The annual general meeting is scheduled for May 29, 2026[92] - The company expresses gratitude to all shareholders and stakeholders for their ongoing support, as well as appreciation for the efforts and contributions of all employees[98] Corporate Governance - The board of directors includes both executive and independent non-executive members, ensuring a diverse governance structure[103] - The audit committee, along with the management and independent auditor, reviewed the accounting principles and policies adopted by the group, confirming that the annual performance aligns with applicable accounting standards and regulations[95] - The consolidated financial statements for the year ending December 31, 2025, have been agreed upon by the group's auditor, ensuring consistency with the audited financial statements[96] Company Background - The company was registered in the Cayman Islands on December 11, 2020, as a limited liability company[99] - The shares of the company were listed on the main board of the Hong Kong Stock Exchange on December 29, 2022[99] - The company adopted a share incentive plan on December 2, 2023, to motivate and reward employees[100] - The reporting period for the financial statements is from January 1, 2025, to December 31, 2025[100]
GUANZE MEDICAL(02427) - 2025 - 年度业绩